髓系来源的抑制性细胞在血液系统恶性肿瘤中的作用。
The role of myeloid-derived suppressor cells in hematologic malignancies.
机构信息
Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Medical Center.
Beckman Research Institute.
出版信息
Curr Opin Oncol. 2020 Sep;32(5):518-526. doi: 10.1097/CCO.0000000000000662.
Abstract
PURPOSE OF REVIEW
This article focuses on the immunosuppressive impact of myeloid-derived suppressor cells (MDSCs) and the potential clinical implications in hematological malignancies.
RECENT FINDINGS
MDSCs play a critical role in the regulation of the immune response in cancer. They inhibit activation of adaptive immune response and as a result foster the growth of the malignancy. Recent studies have shown that MDSCs serve as prognostic biomarkers and as targets for cancer immunotherapy. Preclinical and clinical studies have identified new approaches to deplete MDSC populations and inhibit MDSC function with combination immunomodulatory therapies including chemotherapeutic agents with immune checkpoint-directed treatment.
SUMMARY
A broad spectrum of publications indicate that direct targeting of MDSCs may abrogate their protumorigenic impact within the tumor microenvironment through activation of the adaptive immune response.
摘要
目的综述
本文重点介绍髓系来源抑制细胞（MDSCs）的免疫抑制作用及其在血液恶性肿瘤中的潜在临床意义。
最近发现
MDSCs 在癌症免疫反应的调控中起着关键作用。它们抑制适应性免疫反应的激活，从而促进恶性肿瘤的生长。最近的研究表明，MDSCs 可作为预后生物标志物，并可作为癌症免疫治疗的靶点。临床前和临床研究已经确定了新的方法来消耗 MDSC 群体，并通过联合免疫调节治疗抑制 MDSC 功能，包括化疗药物与免疫检查点靶向治疗。
总结
大量文献表明，通过激活适应性免疫反应，直接针对 MDSC 可能会消除其在肿瘤微环境中的促肿瘤作用。
相似文献
1
The role of myeloid-derived suppressor cells in hematologic malignancies.髓系来源的抑制性细胞在血液系统恶性肿瘤中的作用。
Curr Opin Oncol. 2020 Sep;32(5):518-526. doi: 10.1097/CCO.0000000000000662.
2
Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.单核细胞来源的髓系抑制细胞在血液系统恶性肿瘤中的作用。
Int J Mol Sci. 2019 Nov 1;20(21):5459. doi: 10.3390/ijms20215459.
3
Targeting myeloid-derived suppressor cells for cancer immunotherapy.针对髓系来源的抑制细胞的癌症免疫治疗。
Cancer Immunol Immunother. 2018 Aug;67(8):1181-1195. doi: 10.1007/s00262-018-2175-3. Epub 2018 May 31.
4
Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression.髓源性抑制细胞来源的外泌体在肿瘤免疫和癌症进展中的作用。
Front Immunol. 2022 Jan 27;13:817942. doi: 10.3389/fimmu.2022.817942. eCollection 2022.
5
Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.肿瘤中的髓源性抑制细胞：从机制到抗原特异性和微环境调节。
Front Immunol. 2020 Jul 22;11:1371. doi: 10.3389/fimmu.2020.01371. eCollection 2020.
6
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.髓源性抑制细胞作为癌症中免疫抑制调节因子及治疗靶点。
Signal Transduct Target Ther. 2021 Oct 7;6(1):362. doi: 10.1038/s41392-021-00670-9.
7
Myeloid-derived suppressor cells-new and exciting players in lung cancer.髓系来源的抑制细胞——肺癌中新兴的令人兴奋的角色。
J Hematol Oncol. 2020 Jan 31;13(1):10. doi: 10.1186/s13045-020-0843-1.
8
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.肿瘤进展过程中髓源性抑制细胞（MDSCs）介导的免疫抑制。
Br J Cancer. 2019 Jan;120(1):16-25. doi: 10.1038/s41416-018-0333-1. Epub 2018 Nov 9.
9
Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.肿瘤微环境中髓系来源抑制细胞的扩增与功能
Cancer Lett. 2016 Sep 28;380(1):253-6. doi: 10.1016/j.canlet.2015.10.022. Epub 2015 Oct 28.
10
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.肿瘤微环境中的髓系免疫抑制和免疫检查点。
Cell Mol Immunol. 2020 Jan;17(1):1-12. doi: 10.1038/s41423-019-0306-1. Epub 2019 Oct 14.
引用本文的文献
1
The AXL-mediated modulation of myeloid-derived suppressor cells (MDSC) in nasopharyngeal carcinoma.AXL 介导的鼻咽癌中髓系来源抑制细胞（MDSC）的调节。
Med Oncol. 2024 Nov 27;42(1):17. doi: 10.1007/s12032-024-02561-9.
2
Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma.多重空间分析显示，难治性经典霍奇金淋巴瘤中 CD137 表达增加且 m-MDSC 与肿瘤细胞相邻。
Oncoimmunology. 2024 Aug 10;13(1):2388304. doi: 10.1080/2162402X.2024.2388304. eCollection 2024.
3
Insights of immune cell heterogeneity, tumor-initiated subtype transformation, drug resistance, treatment and detecting technologies in glioma microenvironment.胶质瘤微环境中免疫细胞异质性、肿瘤起始亚型转化、耐药性、治疗及检测技术的见解
J Adv Res. 2025 Jun;72:527-554. doi: 10.1016/j.jare.2024.07.033. Epub 2024 Aug 5.
4
Myeloid-derived suppressor cell mitochondrial fitness governs chemotherapeutic efficacy in hematologic malignancies.髓系来源的抑制性细胞线粒体功能状态决定血液系统恶性肿瘤的化疗疗效。
Nat Commun. 2024 Mar 30;15(1):2803. doi: 10.1038/s41467-024-47096-9.
5
Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies.血液系统恶性肿瘤免疫治疗中的新兴治疗靶点及耐药机制
Cancers (Basel). 2023 Dec 8;15(24):5765. doi: 10.3390/cancers15245765.
6
Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis.骨髓增生性肿瘤患者骨髓中髓源性抑制细胞频率增加：在骨髓纤维化中的潜在影响。
Adv Exp Med Biol. 2023;1408:273-290. doi: 10.1007/978-3-031-26163-3_15.
7
Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies.髓源性抑制细胞对血液系统恶性肿瘤中T细胞功能的调节作用
Front Cell Dev Biol. 2023 Apr 5;11:1129343. doi: 10.3389/fcell.2023.1129343. eCollection 2023.
8
Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies.髓源性抑制细胞：血液系统恶性肿瘤中的关键免疫抑制调节因子及治疗靶点
Biomark Res. 2023 Mar 29;11(1):34. doi: 10.1186/s40364-023-00475-8.
9
The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers.髓系来源的抑制细胞在血液系统恶性肿瘤中的预后价值和治疗靶点。
Front Immunol. 2022 Oct 11;13:1016059. doi: 10.3389/fimmu.2022.1016059. eCollection 2022.
10
New Perspectives on Myeloid-Derived Suppressor Cells and Their Emerging Role in Haematology.髓源性抑制细胞的新视角及其在血液学中的新兴作用
J Clin Med. 2022 Sep 10;11(18):5326. doi: 10.3390/jcm11185326.
本文引用的文献
1
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.髓源性抑制细胞作为癌症治疗靶点。
Cells. 2020 Feb 27;9(3):561. doi: 10.3390/cells9030561.
2
Monocytic myeloid-derived suppressor cells in chronic lymphocytic leukemia patients: a single center experience.慢性淋巴细胞白血病患者中的单核细胞髓系来源抑制细胞：单中心经验。
Leuk Lymphoma. 2020 Jul;61(7):1645-1652. doi: 10.1080/10428194.2020.1728747. Epub 2020 Feb 20.
3
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity.靶向敲除髓系细胞中的 PD-1 可诱导抗肿瘤免疫。
Sci Immunol. 2020 Jan 3;5(43). doi: 10.1126/sciimmunol.aay1863.
4
Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.流式细胞术和靶向免疫转录组学鉴定了接受酪氨酸激酶抑制剂联合或不联合干扰素-α治疗的慢性髓性白血病患者的不同特征。
J Transl Med. 2020 Jan 3;18(1):2. doi: 10.1186/s12967-019-02194-x.
5
Myeloid-driven mechanisms as barriers to antitumor CD8 T cell activity.髓系细胞驱动的机制是抗肿瘤 CD8 T 细胞活性的障碍。
Mol Immunol. 2020 Feb;118:165-173. doi: 10.1016/j.molimm.2019.12.012. Epub 2019 Dec 26.
6
CD8 T cells exhaustion induced by myeloid-derived suppressor cells in myelodysplastic syndromes patients might be through TIM3/Gal-9 pathway.髓系来源抑制细胞诱导骨髓增生异常综合征患者 CD8 T 细胞耗竭可能通过 TIM3/Gal-9 通路。
J Cell Mol Med. 2020 Jan;24(1):1046-1058. doi: 10.1111/jcmm.14825. Epub 2019 Nov 22.
7
Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression.肿瘤遗传改变和免疫微环境特征促使骨髓增生异常综合征逃逸和进展。
Cancer Immunol Immunother. 2019 Dec;68(12):2015-2027. doi: 10.1007/s00262-019-02420-x. Epub 2019 Nov 8.
8
Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.单核细胞来源的髓系抑制细胞在血液系统恶性肿瘤中的作用。
Int J Mol Sci. 2019 Nov 1;20(21):5459. doi: 10.3390/ijms20215459.
9
Myeloid-derived suppressor cells in hematological malignancies: friends or foes.髓系来源的抑制性细胞在血液系统恶性肿瘤中的作用：是敌是友？
J Hematol Oncol. 2019 Oct 22;12(1):105. doi: 10.1186/s13045-019-0797-3.
10
Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer.髓系来源的抑制性细胞在癌症免疫检查点抑制剂治疗中的作用。
Arch Pharm Res. 2019 Jul;42(7):560-566. doi: 10.1007/s12272-019-01165-6. Epub 2019 May 30.
Zotero 插件